AAN has issued a practice guideline update for vaccine-preventable infections and immunizations for individuals with multiple sclerosis (MS). A subcommittee of the AAN — tasked with developing, disseminating and implementing these guidelines — found improvements and additions to the recommendations previously issued in 2002.
Early initiation of highly effective escalation therapies in pediatric patients with MS is associated with reduced cognitive impairment and may prevent cognitive decline.
Vumerity (diroximel fumarate; Biogen) has been approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
With an improved specificity, an updated algorithm for the detection of UTIs in patients with relapsing MS addresses previous issues concerning the unnecessary prescription of antibiotics, whilst improving accuracy and maintaining safety.
Reduction in peripapillary retinal nerve fiber layer (pRNFL) thickness is significantly associated with physical and cognitive disability in patients with multiple sclerosis.
